Search

Your search keyword '"Venky Venkatesh"' showing total 9 results
Start Over Author "Venky Venkatesh"
9 results on '"Venky Venkatesh"'

1. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam)

Author

Howard H. Feldman, José A. Luchsinger, Gabriel C. Léger, Curtis Taylor, Diane M. Jacobs, David P. Salmon, Steven D. Edland, Karen Messer, Carolyn Revta, Sarah A. Flowers, Kerry S. Jones, Albert Koulman, Kevin E. Yarasheski, Philip B. Verghese, Venky Venkatesh, Henrik Zetterberg, January Durant, Jody-Lynn Lupo, and Gary E. Gibson

Subjects
Medicine, Science
Published
2024

2. Plasma Aβ42/40 and cognitive variability are associated with cognitive function in Black Americans: Findings from the AA‐FAIM cohort

Author

Barbara Fischer, Carol Ann Van Hulle, Rebecca Langhough, Derek Norton, Megan Zuelsdorff, Diane Carol Gooding, Mary F. Wyman, Adrienne Johnson, Nickolas Lambrou, Taryn James, Shenikqua Bouges, Fabu Phillis Carter, Hector Salazar, Kristopher Kirmess, Mary Holubasch, Matthew Meyer, Venky Venkatesh, Tim West, Philip Verghese, Kevin Yarasheski, Cynthia M. Carlsson, Sterling C. Johnson, Sanjay Asthana, and Carey E. Gleason

Subjects
Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
Abstract

Abstract Introduction It is critical to develop more inclusive Alzheimer's disease (AD) research protocols to ensure that historically excluded groups are included in preclinical research and have access to timely diagnosis and treatment. If validated in racialized groups, plasma AD biomarkers and measures of subtle cognitive dysfunction could provide avenues to expand diversity in preclinical AD research. We sought to evaluate the utility of two easily obtained, low‐burden disease markers, plasma amyloid beta (Aβ)42/40, and intra‐individual cognitive variability (IICV), to predict concurrent and longitudinal cognitive performance in a sample of Black adults. Methods Two hundred fifty‐seven Black participants enrolled in the African Americans Fighting Alzheimer's in Midlife (AA‐FAIM) study underwent at least one cognitive assessment visit; a subset of n = 235 had plasma samples. Baseline IICV was calculated as the standard deviation across participants’ z scores on five cognitive measures: Rey Auditory Verbal Learning Test Delayed Recall, Trail Making Test Parts A and B (Trails A and B), and Boston Naming Test. Using mixed effects regression models, we compared concurrent and longitudinal models to baseline plasma Aβ42/40 or IICV by age interactions. PrecivityAD assays quantified baseline plasma Aβ42/40. Results IICV was associated with concurrent/baseline performance on several outcomes but did not modify associations between age and cognitive decline. In contrast, plasma Aβ42/40 was unrelated to baseline cognitive performance, but a pattern emerged in interactions with age in longitudinal models of Trails A and B and Rey Auditory Verbal Learning Test total learning trials. Although not significant after correcting for multiple comparisons, low Aβ42/40 was associated with faster cognitive declines over time. Discussion Our results are promising as they extend existing findings to an Black American sample using low‐cost, low‐burden methods that can be implemented outside of a research center, thus supporting efforts for inclusive AD biomarker research.

Published
2023
Full Text
View/download PDF

4. Diabetes is related to cognition but not plasma amyloid‐β 42/40 in an African American cohort

Author

Gilda E. Ennis, Shenikqua Bouges, Megan Zuelsdorff, Carol A. Van Hulle, Erin M. Jonaitis, Rebecca Langhough Koscik, Nickolas H. Lambrou, Hector Salazar, Fabu P Carter, Taryn T. James, Adrienne L. Johnson, Barbara L. Fischer, Kris Kirmess, Mary S. Holubasch, Matthew R. Meyer, Venky Venkatesh, Tim West, Philip B. Verghese, Kevin E. Yarasheski, Nathaniel A. Chin, Sanjay Asthana, Cynthia M. Carlsson, Sterling C. Johnson, Barbara B. Bendlin, and Carey E. Gleason

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

5. An examination of baseline plasma Aβ42/40 and intra‐individual cognitive variability (IICV) associations with longitudinal cognitive change in a Black Cohort: Data from the African Americans Fighting Alzheimer’s in Midlife (AA‐FAIM) study

Author

Carey E. Gleason, Rebecca Langhough Koscik, Megan Zuelsdorff, Derek L. Norton, Barbara L. Fischer, Carol A. Van Hulle, Diane C. Gooding, Kevin E. Yarasheski, Mary F. Wyman, Adrienne L. Johnson, Nickolas H. Lambrou, Taryn T. James, Shenikqua Bouges, Fabu P Carter, Hector Salazar, Nia Norris, Nathaniel A. Chin, Gilda E. Ennis, Erin M. Jonaitis, Carola A. Ferrer Simó, Kris Kirmess, Matthew R. Meyer, Mary S. Holubasch, Venky Venkatesh, Tim West, Philip B. Verghese, Cynthia M. Carlsson, Sanjay Asthana, and Sterling C. Johnson

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

6. Plasma Aβ42/40 and PET amyloid associations among late‐middle‐aged African Americans: Preliminary results from the AA‐FAIM study

Author

Rebecca Langhough Koscik, Tobey J Betthauser, Carol A. Van Hulle, Megan Zuelsdorff, Hector Salazar, Fabu P Carter, Nia Norris, Gina Green‐Harris, Barbara L. Fischer, Nathaniel A. Chin, Diane C. Gooding, Karly Alex Cody, Matthew R. Meyer, Mary S. Holubasch, Kristopher M. Kirmess, Philip B. Verghese, Tim West, Venky Venkatesh, Kevin E. Yarasheski, Bradley T Christian, Sterling C. Johnson, and Carey E. Gleason

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

7. Trajectories of plasma Aβ42/40 among African Americans: Preliminary results from the African American Fighting Alzheimer’s in Midlife (AA‐FAIM) study

Author

Carol A. Van Hulle, Megan Zuelsdorff, Rebecca Langhough Koscik, Gilda E. Ennis, Shenikqua Bouges, Barbara L. Fischer, Mary F. Wyman, Nickolas H. Lambrou, Adrienne L. Johnson, Emre Umucu, Hector Salazar, Nathaniel A. Chin, Matthew R. Meyer, Mary S. Holubasch, Kris Kirmess, Philip B. Verghese, Tim West, Venky Venkatesh, Kevin E. Yarasheski, and Carey E. Gleason

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

8. Plasma ratio of phospho‐ to non‐phospho‐tau at threonine 217 identifies brain amyloid burden as measured by quantitative amyloid PET in the PARIS sub‐study of IDEAS

Author

Matthew R. Meyer, Kristopher M. Kirmess, Traci L. Wente‐Roth, Faith Irvin, Mary S. Holubasch, Philip B. Verghese, Mark Monane, Randall J. Bateman, David M. Holtzman, Venky Venkatesh, Ilana Fogelman, Kevin E. Yarasheski, Joel B. Braunstein, and Tim West

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology
Published
2022
Full Text
View/download PDF

9. Bioinformatics in the pre- and post-genomic eras

Author

Hwa A Lim and T.V.(Venky) Venkatesh

Subjects
business.industry, Bioengineering, Biology, Bioinformatics, Proteomics, Genome, Structural genomics, Pharmacogenomics, Human genome, Personalized medicine, business, Pre and post, Organism, Biotechnology
Abstract

This conference brought forth many novel software tools and techniques, in addition to presenting the challenges we still have to tackle as we move into the next millennium. It seems likely that a complete draft of the human genome will be available by the year 2001. Currently, the critical challenges are the development of novel software tools and techniques for analyzing the data obtained; statistics will play an important role. As we move from the pre-genomic to the post-genomic era, research methodology has also changed from, for example, analysis of a biological problem of a single gene, to that of analysis of biological problems in multiple dimensions.The challenges in the post-genomic era will be pharmacogenomics (individualized medicine), proteomics (derivations of quantitative information on proteins present in different tissues, cells and sub-cellular fractions) and other omics, that is, studies of entities in aggregate, be it DNA, RNA, protein or other molecular complements of a cell, tissue or organism.

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results